VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant ...

The drug, vepdegestrant, failed to meaningfully delay cancer progression for all patients enrolled in the study but met its ...

Pfizer (PFE) stock gains as company appoints James List, a former J&J (JNJ) executive as Chief Internal Medicine Officer to ...

As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert ...

Pfizer Supercharges Obesity Battle with Top J&J Exec ...

A Brooklyn brownstone with a long history starting with the Pfizer family has hit the market for $10.35 million—after setting ...

Pfizer (NYSE:PFE) has named James List ... officer to boost the company's efforts in obesity drug development. The New York-based pharma giant said that List, who has done his post-doctoral ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

By Yasmeen Abutaleb and Michael Erman WASHINGTON/NEW YORK (Reuters) - Pfizer Inc (N:PFE) said on Tuesday it was deferring drug ...